Health Economics›Urothelial carcinoma›Neoadjuvant chemotherapy

Neoadjuvant chemotherapy

Urothelial carcinoma · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	~24.3 mo	~2	~R 62 509 PFS proxy · indirect	3

1 of 1 regimen shown